JP2022508183A - 神経芽細胞腫の治療における使用のためのオーロラａキナーゼ阻害剤 - Google Patents
神経芽細胞腫の治療における使用のためのオーロラａキナーゼ阻害剤 Download PDFInfo
- Publication number
- JP2022508183A JP2022508183A JP2021529009A JP2021529009A JP2022508183A JP 2022508183 A JP2022508183 A JP 2022508183A JP 2021529009 A JP2021529009 A JP 2021529009A JP 2021529009 A JP2021529009 A JP 2021529009A JP 2022508183 A JP2022508183 A JP 2022508183A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- fluoro
- compound
- pyridyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010029260 Neuroblastoma Diseases 0.000 title claims abstract description 33
- 238000011282 treatment Methods 0.000 title claims abstract description 19
- 102000004000 Aurora Kinase A Human genes 0.000 title abstract description 7
- 108090000461 Aurora Kinase A Proteins 0.000 title abstract description 7
- 229940043355 kinase inhibitor Drugs 0.000 title description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 41
- 150000001875 compounds Chemical class 0.000 claims description 55
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 32
- -1 3-chloro-2-fluoro-phenyl Chemical group 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- YQQZZYYQTCPEAS-OYLFLEFRSA-N ClC=1C(=C(C=CC=1)CN1[C@@H](C[C@@](CC1)(C(=O)O)CC1=NC(=CC=C1F)NC1=NNC(=C1)C)C)F Chemical compound ClC=1C(=C(C=CC=1)CN1[C@@H](C[C@@](CC1)(C(=O)O)CC1=NC(=CC=C1F)NC1=NNC(=C1)C)C)F YQQZZYYQTCPEAS-OYLFLEFRSA-N 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 7
- 102000055056 N-Myc Proto-Oncogene Human genes 0.000 description 6
- 108091008800 n-Myc Proteins 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 102000003989 Aurora kinases Human genes 0.000 description 2
- 108090000433 Aurora kinases Proteins 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- XKVUYEYANWFIJX-UHFFFAOYSA-N 5-methyl-1h-pyrazole Chemical compound CC1=CC=NN1 XKVUYEYANWFIJX-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-CDMOMSTLSA-N 9,13-cis-Retinoic acid Chemical compound OC(=O)\C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-CDMOMSTLSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical class N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 101150022024 MYCN gene Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 239000003719 aurora kinase inhibitor Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960004497 dinutuximab Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000011228 multimodal treatment Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023016982A JP2023058582A (ja) | 2018-11-30 | 2023-02-07 | 神経芽細胞腫の治療における使用のためのオーロラａキナーゼ阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773367P | 2018-11-30 | 2018-11-30 | |
| US62/773,367 | 2018-11-30 | ||
| PCT/US2019/062718 WO2020112514A1 (fr) | 2018-11-30 | 2019-11-22 | Inhibiteur de kinase aurora a destiné à être utilisé dans le traitement du neuroblastome |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023016982A Division JP2023058582A (ja) | 2018-11-30 | 2023-02-07 | 神経芽細胞腫の治療における使用のためのオーロラａキナーゼ阻害剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2022508183A true JP2022508183A (ja) | 2022-01-19 |
Family
ID=68916597
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529009A Pending JP2022508183A (ja) | 2018-11-30 | 2019-11-22 | 神経芽細胞腫の治療における使用のためのオーロラａキナーゼ阻害剤 |
| JP2023016982A Withdrawn JP2023058582A (ja) | 2018-11-30 | 2023-02-07 | 神経芽細胞腫の治療における使用のためのオーロラａキナーゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023016982A Withdrawn JP2023058582A (ja) | 2018-11-30 | 2023-02-07 | 神経芽細胞腫の治療における使用のためのオーロラａキナーゼ阻害剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220000855A1 (fr) |
| EP (1) | EP3886855A1 (fr) |
| JP (2) | JP2022508183A (fr) |
| KR (1) | KR20210084555A (fr) |
| CN (1) | CN113038950A (fr) |
| AU (1) | AU2019388843B2 (fr) |
| BR (1) | BR112021006578A2 (fr) |
| CA (1) | CA3121483A1 (fr) |
| EA (1) | EA202191051A1 (fr) |
| IL (1) | IL282270A (fr) |
| MA (1) | MA54290A (fr) |
| MX (1) | MX2021006011A (fr) |
| SG (1) | SG11202104344RA (fr) |
| UA (1) | UA125892C2 (fr) |
| WO (1) | WO2020112514A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI785474B (zh) * | 2020-01-22 | 2022-12-01 | 大陸商北京加科思新藥研發有限公司 | 用作選擇性Aurora A抑制劑的新型雜環化合物 |
| CN117836285A (zh) * | 2021-07-28 | 2024-04-05 | 北京加科思新药研发有限公司 | Aurora a选择性抑制剂的多晶型及其用途 |
| WO2023196887A1 (fr) | 2022-04-08 | 2023-10-12 | Eli Lilly And Company | Méthode de traitement comprenant des inhibiteurs de kras g12c et des inhibiteurs d'aurora a |
| WO2024003360A1 (fr) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarqueurs et leurs utilisations pour le traitement du neuroblastome |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016539942A (ja) * | 2014-11-14 | 2016-12-22 | イーライ リリー アンド カンパニー | オーロラａキナーゼ阻害剤 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9576309B2 (en) | 2014-11-12 | 2017-02-21 | Snergy Inc. | Dynamic power sharing system and map view graphical user interface |
-
2019
- 2019-11-22 EP EP19821387.8A patent/EP3886855A1/fr not_active Withdrawn
- 2019-11-22 BR BR112021006578-4A patent/BR112021006578A2/pt unknown
- 2019-11-22 AU AU2019388843A patent/AU2019388843B2/en not_active Ceased
- 2019-11-22 CN CN201980077760.3A patent/CN113038950A/zh active Pending
- 2019-11-22 CA CA3121483A patent/CA3121483A1/fr active Pending
- 2019-11-22 KR KR1020217015919A patent/KR20210084555A/ko not_active Application Discontinuation
- 2019-11-22 JP JP2021529009A patent/JP2022508183A/ja active Pending
- 2019-11-22 WO PCT/US2019/062718 patent/WO2020112514A1/fr active Application Filing
- 2019-11-22 MA MA054290A patent/MA54290A/fr unknown
- 2019-11-22 MX MX2021006011A patent/MX2021006011A/es unknown
- 2019-11-22 EA EA202191051A patent/EA202191051A1/ru unknown
- 2019-11-22 SG SG11202104344RA patent/SG11202104344RA/en unknown
- 2019-11-22 US US17/295,721 patent/US20220000855A1/en active Pending
- 2019-11-22 UA UAA202101953A patent/UA125892C2/uk unknown
-
2021
- 2021-04-12 IL IL282270A patent/IL282270A/en unknown
-
2023
- 2023-02-07 JP JP2023016982A patent/JP2023058582A/ja not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016539942A (ja) * | 2014-11-14 | 2016-12-22 | イーライ リリー アンド カンパニー | オーロラａキナーゼ阻害剤 |
Non-Patent Citations (5)
| Title |
|---|
| "433 Genomic predictors of therapeutic sensitivity to TAS-119, a selective inhibitor of Aurora-A kina", EUROPEAN JOURNAL OF CANCER, vol. vol.50, supp. suppl.6, JPN6022020777, 2014, pages 142 - 143, ISSN: 0004893808 * |
| "Illuminating Aurora dependencies", SCIENCE TRANSLATIONAL MEDICINE, vol. 10, no. 467, JPN6022020775, 14 November 2018 (2018-11-14), ISSN: 0004893810 * |
| CANCER DISCOVERY, vol. 9, no. 2, JPN6022020776, 29 October 2018 (2018-10-29), pages 248 - 263, ISSN: 0004893809 * |
| JOURNAL OF CLINICAL ONCOLOGY, vol. 34, no. 12, JPN6022020778, 2016, pages 1368 - 1375, ISSN: 0004893807 * |
| PLOS ONE, vol. vol.9, no.9, e108758, JPN6022020779, 2014, ISSN: 0004893806 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3886855A1 (fr) | 2021-10-06 |
| US20220000855A1 (en) | 2022-01-06 |
| AU2019388843B2 (en) | 2023-03-23 |
| EA202191051A1 (ru) | 2021-08-26 |
| BR112021006578A2 (pt) | 2021-07-27 |
| WO2020112514A1 (fr) | 2020-06-04 |
| AU2019388843A1 (en) | 2021-05-20 |
| MX2021006011A (es) | 2021-09-21 |
| IL282270A (en) | 2021-05-31 |
| KR20210084555A (ko) | 2021-07-07 |
| JP2023058582A (ja) | 2023-04-25 |
| MA54290A (fr) | 2022-03-09 |
| CN113038950A (zh) | 2021-06-25 |
| SG11202104344RA (en) | 2021-05-28 |
| UA125892C2 (uk) | 2022-06-29 |
| CA3121483A1 (fr) | 2020-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6798890B2 (ja) | グルタミナーゼ阻害剤との併用療法 | |
| JP2022508183A (ja) | 神経芽細胞腫の治療における使用のためのオーロラａキナーゼ阻害剤 | |
| RU2685250C2 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ ИНГИБИТОРА CDK4/6 И ИНГИБИТОРА В-Raf | |
| CN110022900A (zh) | 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合 | |
| KR102258698B1 (ko) | B-Raf 억제제와 제2 억제제를 포함하는 조합 요법 | |
| TWI607754B (zh) | 醫藥組合 | |
| JP2016529245A (ja) | 固形腫瘍の処置方法 | |
| EP4119557A1 (fr) | Combinaison pharmaceutique comprenant un composé pyridino[1,2-a]pyrimidinone | |
| AU2020381240C1 (en) | Therapeutic combinations of acalabrutinib and capivasertib to treat B-cell malignancies | |
| AU2016308704B2 (en) | MDM2 inhibitors for treating uveal melanoma | |
| KR20210091758A (ko) | Mcl-1 억제제와 미도스타우린의 조합물, 이의 용도 및 약학적 조성물 | |
| US20160151344A1 (en) | Compounds for use in the treatment of neuroblastoma, ewing's sarcoma or rhabdomyosarcoma | |
| BR112021011699A2 (pt) | Terapia de combinação com um inibidor de raf e um inibidor de cdk4/6 para uso no tratamento contra câncer | |
| WO2018133838A1 (fr) | Utilisations d'un inhibiteur de egfr/her2 combiné à un médicament anti-métabolique de type pyrimidine | |
| JP4522261B2 (ja) | ブドウ膜黒色腫の処置 | |
| TW202228703A (zh) | 一種吡啶并[1,2-a]嘧啶酮類似物的應用 | |
| WO2024114740A1 (fr) | Utilisation d'un composé de quinoléine dans le traitement du cancer de la thyroïde | |
| EA045670B1 (ru) | Терапевтические комбинации акалабрутиниба и капивасертиба для лечения в-клеточных злокачественных образований | |
| JP2009108058A (ja) | 抗リンパ腫組成物および方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210521 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210521 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220531 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221011 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20230207 |